Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fuller departing NACDS?

This article was originally published in The Tan Sheet

Executive Summary

The Board of the National Association of Chain Drug Stores is discussing the possible departure of CEO Craig Fuller, the association states March 14. Fuller has met with the Board and Chairman Anthony Civello (Kerr Drug) to discuss the matter and has offered to tender his resignation, but no decision has been made, NACDS says. However, the board did indicate it was moving in a different direction, the association said. The drug store space finds itself under pressure from reduced pharmacy reimbursement under the Medicaid program and the potential of an FDA-mandated electronic pedigree system for tracking drugs. The upper limit for reimbursement of multiple source drugs under Medicaid was modified in the Deficit Reduction Act (S 1932), which was largely considered a setback for pharmacy. Fuller had been cautiously optimistic that the bill's passage could be blocked, but it narrowly passed Congress with Vice President Cheney casting a tie-breaking vote. Fuller has worked in the White House under Presidents Reagan and Bush...

You may also be interested in...

Fuller departure

NACDS President & CEO Craig Fuller is resigning as of April 7, the exec confirms in his weekly newsletter March 20. "When it comes time to explore new directions and new leadership, presidents and boards are supposed to send a signal that it is time for a change. That signal has been sent in a remarkably professional and constructive manner," Fuller says. The chain drug store association indicated March 14 that its board had met with Fuller, who had offered his resignation (1"The Tan Sheet" March 20, 2006 , In Brief)...

Akorn Defaults On Loan Agreement After Sale Bid Falls Flat

Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.

Pipeline Watch: Vericiguat, Evinacumab Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts